Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
92% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. DSCI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DSCI' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.62 Max: No Debt
Current: No Debt
Equity to Asset 0.86
DSCI's Equity to Asset is ranked higher than
87% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. DSCI: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
DSCI' s Equity to Asset Range Over the Past 10 Years
Min: 0.46  Med: 0.66 Max: 0.9
Current: 0.86
0.46
0.9
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
93% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.66 vs. DSCI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DSCI' s Interest Coverage Range Over the Past 10 Years
Min: 3.51  Med: 10000.00 Max: 9999.99
Current: No Debt
3.51
9999.99
F-Score: 4
Z-Score: 2.43
M-Score: -2.64
WACC vs ROIC
7.51%
-36.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -26.00
DSCI's Operating margin (%) is ranked lower than
77% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. DSCI: -26.00 )
Ranked among companies with meaningful Operating margin (%) only.
DSCI' s Operating margin (%) Range Over the Past 10 Years
Min: -47.89  Med: -5.98 Max: 4.71
Current: -26
-47.89
4.71
Net-margin (%) -45.11
DSCI's Net-margin (%) is ranked lower than
78% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. DSCI: -45.11 )
Ranked among companies with meaningful Net-margin (%) only.
DSCI' s Net-margin (%) Range Over the Past 10 Years
Min: -47.49  Med: -7.41 Max: 2.4
Current: -45.11
-47.49
2.4
ROE (%) -34.21
DSCI's ROE (%) is ranked lower than
79% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.01 vs. DSCI: -34.21 )
Ranked among companies with meaningful ROE (%) only.
DSCI' s ROE (%) Range Over the Past 10 Years
Min: -39.24  Med: -14.87 Max: 6.13
Current: -34.21
-39.24
6.13
ROA (%) -30.40
DSCI's ROA (%) is ranked lower than
82% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. DSCI: -30.40 )
Ranked among companies with meaningful ROA (%) only.
DSCI' s ROA (%) Range Over the Past 10 Years
Min: -34.91  Med: -10.04 Max: 4.65
Current: -30.4
-34.91
4.65
ROC (Joel Greenblatt) (%) -108.91
DSCI's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. DSCI: -108.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DSCI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -208.01  Med: -23.30 Max: 14.74
Current: -108.91
-208.01
14.74
Revenue Growth (3Y)(%) -17.40
DSCI's Revenue Growth (3Y)(%) is ranked lower than
87% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. DSCI: -17.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DSCI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.6  Med: -12.30 Max: 19.6
Current: -17.4
-39.6
19.6
EBITDA Growth (3Y)(%) -7.80
DSCI's EBITDA Growth (3Y)(%) is ranked lower than
80% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. DSCI: -7.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DSCI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.50 Max: 107.4
Current: -7.8
0
107.4
EPS Growth (3Y)(%) -6.50
DSCI's EPS Growth (3Y)(%) is ranked lower than
70% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. DSCI: -6.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DSCI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.7  Med: 1.60 Max: 139.2
Current: -6.5
-29.7
139.2
» DSCI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DSCI Guru Trades in Q1 2015

Jim Simons 141,608 sh (+806.41%)
Chuck Royce 342,600 sh (+111.35%)
» More
Q2 2015

DSCI Guru Trades in Q2 2015

Jim Simons 381,907 sh (+169.69%)
Chuck Royce 392,500 sh (+14.57%)
» More
Q3 2015

DSCI Guru Trades in Q3 2015

Jim Simons 281,000 sh (-26.42%)
Chuck Royce 221,507 sh (-43.57%)
» More
Q4 2015

DSCI Guru Trades in Q4 2015

Jim Simons 439,300 sh (+56.33%)
Chuck Royce 237,507 sh (+7.22%)
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.92
DSCI's P/B is ranked higher than
84% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. DSCI: 0.92 )
Ranked among companies with meaningful P/B only.
DSCI' s P/B Range Over the Past 10 Years
Min: 0.5  Med: 1.43 Max: 3.42
Current: 0.92
0.5
3.42
P/S 1.06
DSCI's P/S is ranked higher than
74% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. DSCI: 1.06 )
Ranked among companies with meaningful P/S only.
DSCI' s P/S Range Over the Past 10 Years
Min: 0.2  Med: 0.75 Max: 3.25
Current: 1.06
0.2
3.25
Current Ratio 5.25
DSCI's Current Ratio is ranked higher than
81% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. DSCI: 5.25 )
Ranked among companies with meaningful Current Ratio only.
DSCI' s Current Ratio Range Over the Past 10 Years
Min: 1.54  Med: 2.08 Max: 8.76
Current: 5.25
1.54
8.76
Quick Ratio 3.72
DSCI's Quick Ratio is ranked higher than
78% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. DSCI: 3.72 )
Ranked among companies with meaningful Quick Ratio only.
DSCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.45  Med: 1.36 Max: 7.61
Current: 3.72
0.45
7.61
Days Inventory 120.85
DSCI's Days Inventory is ranked higher than
56% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.91 vs. DSCI: 120.85 )
Ranked among companies with meaningful Days Inventory only.
DSCI' s Days Inventory Range Over the Past 10 Years
Min: 85.54  Med: 109.46 Max: 130.4
Current: 120.85
85.54
130.4
Days Sales Outstanding 35.20
DSCI's Days Sales Outstanding is ranked higher than
89% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.39 vs. DSCI: 35.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
DSCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.37  Med: 35.19 Max: 39.21
Current: 35.2
25.37
39.21
Days Payable 17.45
DSCI's Days Payable is ranked lower than
94% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.99 vs. DSCI: 17.45 )
Ranked among companies with meaningful Days Payable only.
DSCI' s Days Payable Range Over the Past 10 Years
Min: 17.45  Med: 32.99 Max: 66.29
Current: 17.45
17.45
66.29

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.66
DSCI's Price/Net Cash is ranked higher than
81% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.01 vs. DSCI: 3.66 )
Ranked among companies with meaningful Price/Net Cash only.
DSCI' s Price/Net Cash Range Over the Past 10 Years
Min: 3.82  Med: 5.22 Max: 17.74
Current: 3.66
3.82
17.74
Price/Net Current Asset Value 1.64
DSCI's Price/Net Current Asset Value is ranked higher than
92% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. DSCI: 1.64 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DSCI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.79  Med: 2.55 Max: 9.91
Current: 1.64
0.79
9.91
Price/Tangible Book 1.20
DSCI's Price/Tangible Book is ranked higher than
81% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. DSCI: 1.20 )
Ranked among companies with meaningful Price/Tangible Book only.
DSCI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.69  Med: 1.95 Max: 8.85
Current: 1.2
0.69
8.85
Price/Median PS Value 1.41
DSCI's Price/Median PS Value is ranked lower than
75% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. DSCI: 1.41 )
Ranked among companies with meaningful Price/Median PS Value only.
DSCI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.82 Max: 3.61
Current: 1.41
0.11
3.61
Earnings Yield (Greenblatt) (%) -44.51
DSCI's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. DSCI: -44.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DSCI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -44.51  Med: 2.70 Max: 6.7
Current: -44.51
-44.51
6.7

More Statistics

Revenue(Mil) $84
EPS $ -1.49
Beta0.75
Short Percentage of Float1.48%
52-Week Range $2.85 - 8.17
Shares Outstanding(Mil)25.88

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 89 95 102
EPS($) -0.28 -0.04 0.05
EPS without NRI($) -0.28 -0.04 0.05

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:HBIOV, TSE:7702, XKRX:104540, HKSE:00899, BSP:CREM3, NAS:SSRG » details
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. In addition, the Company owns or licenses over 50 U.S. patents, corresponding foreign patents and patent applications. The patents relating to the DSC127, MEDIHONEY, BIOGUARD, AMNIOEXCEL and AMNIOMATRIX technologies are held under license agreements of indefinite duration. It is subject to the regulation regarding occupational safety, laboratory practices, environmental protection and hazardous substance control and may be subject to other present and future U.S. and foreign regulations.
» More Articles for NAS:DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
Derma Sciences Announces AMNIOEXCEL® Is Now Eligible for Reimbursement by Medicare Administrative... Apr 27 2016
Derma Sciences Announces AMNIOEXCEL® Is Now Eligible for Reimbursement by Medicare Administrative... Apr 27 2016
Edited Transcript of DSCI earnings conference call or presentation 16-Mar-16 3:00pm GMT Apr 04 2016
DERMA SCIENCES, INC. Financials Mar 19 2016
Derma Sciences Inc Earnings Call scheduled for 11:00 am ET today Mar 16 2016
Medical Products Companies Tap Into $50 Billion U.S. Government GSA Supply Program Mar 16 2016
Derma Sciences reports 4Q loss Mar 16 2016
Derma Sciences reports 4Q loss Mar 16 2016
Derma Sciences Reports 2015 Fourth Quarter and Full Year Financial Results Mar 16 2016
Q4 2015 Derma Sciences Inc Earnings Release - Before Market Open Mar 16 2016
DERMA SCIENCES, INC. Files SEC form 10-K, Annual Report Mar 15 2016
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 16th Mar 10 2016
Findings from Multicenter Study Comparing Derma Sciences’ AMNIOEXCEL® Against Standard-of-Care... Mar 07 2016
Derma Sciences’ AMNIOEXCEL® Now Eligible for Reimbursement by Medicare Administrative Contractor... Mar 03 2016
DERMA SCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 01 2016
BioLargo Closes Financing To Advance Its Novel Wound Care Products Jan 20 2016
Derma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial Guidance Jan 07 2016
Derma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial Guidance Jan 07 2016
Derma Sciences, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
Is Derma Sciences (DSCI) Stock a Solid Choice Right Now? Dec 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK